Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Pouyiourou, Maria; Kraft, Bianca N.; Wohlfromm, Timothy; Stahl, Michael; Kubuschok, Boris; Loeffler, Harald; Hacker, Ulrich T.; Huebner, Gerdt; Weiss, Lena; Bitzer, Michael; Ernst, Thomas; Schuett, Philipp; Hielscher, Thomas; Delorme, Stefan; Kirchner, Martina; Kazdal, Daniel; Ball, Markus; Kluck, Klaus; Stenzinger, Albrecht; Bochtler, Tilmann; Kraemer, Alwin

dc.contributor.author	Bitzer, Michael
dc.date.accessioned	2024-06-11T05:56:35Z
dc.date.available	2024-06-11T05:56:35Z
dc.date.issued	2023
dc.identifier.issn	2041-1723
dc.identifier.uri	http://hdl.handle.net/10900/154149
dc.language.iso	en	de_DE
dc.publisher	Berlin : Nature Portfolio	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/s41467-023-42400-5	de_DE
dc.subject.ddc	500	de_DE
dc.title	Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240124000000_00663
utue.personen.roh	Pouyiourou, Maria
utue.personen.roh	Kraft, Bianca N.
utue.personen.roh	Wohlfromm, Timothy
utue.personen.roh	Stahl, Michael
utue.personen.roh	Kubuschok, Boris
utue.personen.roh	Loeffler, Harald
utue.personen.roh	Hacker, Ulrich T.
utue.personen.roh	Huebner, Gerdt
utue.personen.roh	Weiss, Lena
utue.personen.roh	Bitzer, Michael
utue.personen.roh	Ernst, Thomas
utue.personen.roh	Schuett, Philipp
utue.personen.roh	Hielscher, Thomas
utue.personen.roh	Delorme, Stefan
utue.personen.roh	Kirchner, Martina
utue.personen.roh	Kazdal, Daniel
utue.personen.roh	Ball, Markus
utue.personen.roh	Kluck, Klaus
utue.personen.roh	Stenzinger, Albrecht
utue.personen.roh	Bochtler, Tilmann
utue.personen.roh	Kraemer, Alwin
dcterms.isPartOf.ZSTitelID	Nature Communications	de_DE
dcterms.isPartOf.ZS-Issue	Article 6761	de_DE
dcterms.isPartOf.ZS-Volume	14 (1)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE